Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM Pathogenic Alleles in Breast and Ovarian Cancer Patients from the North Caucasus

Background: Mountain areas of the North Caucasus host several large ethnic communities that have preserved their national identity over the centuries.

Methods: This study involved high-grade serous ovarian cancer (HGSOC) and breast cancer (BC) patients from Dagestan (HGSOC: 37; BC: 198), Kabardino-Balkaria (HGSOC: 68; BC: 155), North Ossetia (HGSOC: 51; BC: 104), Chechnya (HGSOC: 68; BC: 79), Ingushetia (HGSOC: 19; BC: 103), Karachay-Cherkessia (HGSOC: 13; BC: 47), and several Armenian settlements (HGSOC: 16; BC: 101). The group of BC patients was enriched by young-onset and/or family history-positive and/or bilateral and/or receptor triple-negative cases. The entire coding region of BRCA1, BRCA2, PALB2, and ATM genes was analyzed by next-generation sequencing.

Results: A significant contribution of BRCA1/2 pathogenic variants (PVs) to HGSOC and BC development was observed across all North Caucasus regions (HGSOC: 19-39%; BC: 6-13%). Founder alleles were identified in all ethnic groups studied, e.g., BRCA1 c.3629_3630delAG in Chechens, BRCA2 c.6341delC in North Ossetians, BRCA2 c.5351dupA in Ingush, and BRCA1 c.2907_2910delTAAA in Karachays. Some BRCA1/2 alleles, particularly BRCA2 c.9895C > T, were shared by several nationalities. ATM PVs were detected in 14 patients, with c.1673delG and c.8876_8879delACTG alleles occurring twice each. PALB2 heterozygosity was observed in 5 subjects, with one variant seen in 2 unrelated women.

Conclusion: This study adds to the evidence for the global-wide contribution of BRCA1/2 genes to HGSOC and BC morbidity, although the spectrum of their PVs is a subject of ethnicity-specific variations. The data on founder BRCA1/2 alleles may be considered when adjusting the BRCA1/2 testing procedure to the ethnic origin of patients.

Citing Articles

High- and Moderate-Risk Variants Among Breast Cancer Patients and Healthy Donors Enrolled in Multigene Panel Testing in a Population of Central Russia.

Shumilova S, Danishevich A, Nikolaev S, Krasnov G, Ikonnikova A, Isaeva D Int J Mol Sci. 2024; 25(23).

PMID: 39684352 PMC: 11641773. DOI: 10.3390/ijms252312640.

A Systematic Review of the Prevalence of Germline BRCA mutations in North Asia Breast Cancer Patients.

Gervas P, Aleksey M, Nataliya B, Kollantay O, Evgeny C, Cherdyntseva N Asian Pac J Cancer Prev. 2024; 25(6):1891-1902.

PMID: 38918649 PMC: 11382858. DOI: 10.31557/APJCP.2024.25.6.1891.

References

Miki Y, Swensen J, Futreal P, Harshman K, Tavtigian S, Liu Q . A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266(5182):66-71. DOI: 10.1126/science.7545954. View

Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J . Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995; 378(6559):789-92. DOI: 10.1038/378789a0. View

Rebbeck T, Couch F, Kant J, Calzone K, DeShano M, Peng Y . Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet. 1996; 59(3):547-53. PMC: 1914911. View

Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D . Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010; 42(5):410-4. DOI: 10.1038/ng.569. View

Song H, Dicks E, Ramus S, Tyrer J, Intermaggio M, Hayward J . Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J Clin Oncol. 2015; 33(26):2901-7. PMC: 4554751. DOI: 10.1200/JCO.2015.61.2408. View

Golmard L, Castera L, Krieger S, Moncoutier V, Abidallah K, Tenreiro H . Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers. Eur J Hum Genet. 2017; 25(12):1345-1353. PMC: 5865182. DOI: 10.1038/s41431-017-0021-2. View

Suszynska M, Ratajska M, Kozlowski P . BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. J Ovarian Res. 2020; 13(1):50. PMC: 7196220. DOI: 10.1186/s13048-020-00654-3. View

Antoniou A, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J . Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014; 371(6):497-506. PMC: 4157599. DOI: 10.1056/NEJMoa1400382. View

Abe A, Imoto I, Ueki A, Nomura H, Kanao H . Moderate-Risk Genes for Hereditary Ovarian Cancers Involved in the Homologous Recombination Repair Pathway. Int J Mol Sci. 2022; 23(19). PMC: 9570179. DOI: 10.3390/ijms231911790. View

10.

Imyanitov E, Kuligina E, Sokolenko A, Suspitsin E, Yanus G, Iyevleva A . Hereditary cancer syndromes. World J Clin Oncol. 2023; 14(2):40-68. PMC: 9993141. DOI: 10.5306/wjco.v14.i2.40. View

11.

Nguyen-Dumont T, Karpinski P, Sasiadek M, Akopyan H, Steen J, Theys D . Genetic testing in Poland and Ukraine: should comprehensive germline testing of and be recommended for women with breast and ovarian cancer?. Genet Res (Camb). 2020; 102:e6. PMC: 7443769. DOI: 10.1017/S0016672320000075. View

12.

Sokolenko A, Sokolova T, Ni V, Preobrazhenskaya E, Iyevleva A, Aleksakhina S . Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients. Breast Cancer Res Treat. 2020; 184(1):229-235. DOI: 10.1007/s10549-020-05827-8. View

13.

Yanus G, Savonevich E, Sokolenko A, Romanko A, Ni V, Bakaeva E . Founder vs. non-founder BRCA1/2 pathogenic alleles: the analysis of Belarusian breast and ovarian cancer patients and review of other studies on ethnically homogenous populations. Fam Cancer. 2022; 22(1):19-30. DOI: 10.1007/s10689-022-00296-y. View

14.

Rafnar T, Benediktsdottir K, Eldon B, Gestsson T, Saemundsson H, Olafsson K . BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. Eur J Cancer. 2004; 40(18):2788-93. DOI: 10.1016/j.ejca.2004.09.008. View

15.

Vehmanen P, Friedman L, Eerola H, McClure M, Ward B, Sarantaus L . Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet. 1998; 6(13):2309-15. DOI: 10.1093/hmg/6.13.2309. View

16.

Balanovsky O, Dibirova K, Dybo A, Mudrak O, Frolova S, Pocheshkhova E . Parallel evolution of genes and languages in the Caucasus region. Mol Biol Evol. 2011; 28(10):2905-20. PMC: 3355373. DOI: 10.1093/molbev/msr126. View

17.

Sokolenko A, Sultanova L, Stepanov I, Romanko A, Venina A, Sokolova T . Strong founder effect for BRCA1 c.3629_3630delAG pathogenic variant in Chechen patients with breast or ovarian cancer. Cancer Med. 2022; 12(3):3167-3171. PMC: 9939208. DOI: 10.1002/cam4.5159. View

18.

Kowalik A, Siolek M, Kopczynski J, Krawiec K, Kalisz J, Zieba S . BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study. PLoS One. 2018; 13(7):e0201086. PMC: 6057642. DOI: 10.1371/journal.pone.0201086. View

19.

Savanevich A, Ashuryk O, Cybulski C, Lubinski J, Gronwald J . BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update. Hered Cancer Clin Pract. 2021; 19(1):13. PMC: 7818718. DOI: 10.1186/s13053-021-00169-y. View

20.

Kechin A, Boyarskikh U, Barinov A, Tanas A, Kazakova S, Zhevlova A . A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia. Breast Cancer Res Treat. 2022; 197(2):387-395. DOI: 10.1007/s10549-022-06782-2. View